Pharmacy Diabetes

Dipeptidyl peptidase 4 (DPP4) inhibitors-formulation

  • Modified release tablets in 500 mg and 1000 mg strengths.
  • Unless specified by the brand modified released tablets should not be halved or crushed at any time.
  • This form of Metformin has not been shown to have any increase in adverse effects compared to with the equivalent dose of the immediate release Metformin.
  • There is data to suggest the modified release may cause less gastrointestinal side effects than the immediate release.
Key Practice Points

Inhibit the breakdown of dipeptidyl peptidase-4 enzyme (this enzyme is responsible for or the degradation of incretins such as GLP-1 which are a group of hormones that stimulate a decrease in blood glucose levels).

The most significant effect on glucose levels is after meals

Pharmacokinetic Properties – Summary
Metformin modified release is not altered by the composition of a meal.
Plasma protein binding of metformin is negligible.

Renal clearance of metformin is > 400 mL/min, indicating that metformin is eliminated by glomerular filtration and tubular secretion. Dosage adjustment should occur therefore in those with renal dysfunction and ceased in renal failure.

For more detailed information on this product please consult the product information.